Atara Biotherapeutics Files 8-K

Ticker: ATRA · Form: 8-K · Filed: Jun 17, 2024 · CIK: 1604464

Atara Biotherapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyAtara Biotherapeutics, INC. (ATRA)
Form Type8-K
Filed DateJun 17, 2024
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k, financials

Related Tickers: ATRA

TL;DR

ATRA filed an 8-K, looks like routine docs, no major news yet.

AI Summary

On June 17, 2024, Atara Biotherapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events detailed in the provided text. The company is incorporated in Delaware and its principal executive offices are located in Thousand Oaks, CA.

Why It Matters

This filing indicates a routine update or submission of financial information and exhibits by Atara Biotherapeutics to the SEC.

Risk Assessment

Risk Level: low — The filing appears to be a standard procedural submission without immediate material news impacting the company's operations or stock.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, primarily concerning 'Other Events' and 'Financial Statements and Exhibits'.

When was the earliest event reported in this filing?

The earliest event reported is dated June 17, 2024.

What is Atara Biotherapeutics, Inc.'s state of incorporation?

Atara Biotherapeutics, Inc. is incorporated in Delaware.

Where are Atara Biotherapeutics, Inc.'s principal executive offices located?

The principal executive offices are located at 2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA 91320.

What is the SEC file number for Atara Biotherapeutics, Inc.?

The SEC file number for Atara Biotherapeutics, Inc. is 001-36548.

Filing Stats: 654 words · 3 min read · ~2 pages · Grade level 10.7 · Accepted 2024-06-17 08:30:31

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release, dated June 17, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Atara Biotherapeutics, Inc. By: /s/ Amar Murugan Amar Murugan Executive Vice President and Chief Legal Officer Date: June 17, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing